PUM2: A Potential Drug Target and Biomarker for Diseases (G23369)

Target Name: PUM2

NCBI ID: G23369

PUM2

PUM2: A Potential Drug Target and Biomarker for Diseases

PUM2, or Pumilio-uracil nucleotide diphosphate, is a protein located in the nucleoplasm of human cells. It is a key player in the process of DNA replication and has been shown to play a crucial role in the regulation of gene expression . Several studies have identified PUM2 as a potential drug target and have suggested that inhibiting its activity could be a useful therapy for various diseases.

PUM2 is a 25kDa protein that is composed of a N-terminal alpha-helix, a middle beta-sheet, and a C-terminal terminal beta-sheet. It is located in the nucleoplasm and is involved in the process of DNA replication. PUM2 is one of the eight proteins that are essential for DNA replication, and its activity is critical for the initiation of the replication process.

PUM2 has been shown to play a role in the regulation of gene expression. Studies have shown that PUM2 can interact with several transcription factors, including RNA polymerase II (RNA-P2), which is responsible for the transcription process. This interaction between PUM2 and RNA -P2 suggests that PUM2 may be a negative regulator of RNA-P2 and can potentially inhibit its activity.

In addition to its role in the regulation of gene expression, PUM2 has also been shown to play a role in the development and progression of certain diseases. For example, studies have shown that high levels of PUM2 are associated with the development of certain types of cancer, including breast cancer and lung cancer. Additionally, PUM2 has been shown to be involved in the regulation of the immune response, and high levels of PUM2 have been associated with an increased risk of certain types of autoimmune diseases.

Given its involvement in the regulation of gene expression and its association with the development of certain diseases, PUM2 has been identified as a potential drug target. Studies have shown that several small molecules have been shown to interact with PUM2 and have the potential to inhibit its activity. These small molecules include inhibitors of RNA-P2, which are known to inhibit the activity of RNA-P2, as well as inhibitors of DNA replication itself, such as the drug adenine.

In addition to its potential as a drug target, PUM2 has also been shown to be a biomarker for several diseases. For example, studies have shown that PUM2 levels are elevated in the nucleoplasm of cells that are under stress, such as cells that have been treated with chemotherapy drugs. Additionally, PUM2 has been shown to be elevated in the nucleoplasm of cells that have been infected with certain viruses, such as the flu virus.

Overall, PUM2 is a protein that has important role in the regulation of gene expression and the development and progression of certain diseases. Its potential as a drug target and biomarker make it an attractive target for further research and development. Further studies are needed to fully understand the role of PUM2 in the regulation of gene expression and the development and progression of diseases, as well as to identify safe and effective drugs that can inhibit its activity.

Protein Name: Pumilio RNA Binding Family Member 2

Functions: Sequence-specific RNA-binding protein that acts as a post-transcriptional repressor by binding the 3'-UTR of mRNA targets. Binds to an RNA consensus sequence, the Pumilio Response Element (PRE), 5'-UGUANAUA-3', that is related to the Nanos Response Element (NRE) (, PubMed:21397187). Mediates post-transcriptional repression of transcripts via different mechanisms: acts via direct recruitment of the CCR4-POP2-NOT deadenylase leading to translational inhibition and mRNA degradation (PubMed:22955276). Also mediates deadenylation-independent repression by promoting accessibility of miRNAs (PubMed:18776931, PubMed:22345517). Acts as a post-transcriptional repressor of E2F3 mRNAs by binding to its 3'-UTR and facilitating miRNA regulation (PubMed:22345517). Plays a role in cytoplasmic sensing of viral infection (PubMed:25340845). Represses a program of genes necessary to maintain genomic stability such as key mitotic, DNA repair and DNA replication factors. Its ability to repress those target mRNAs is regulated by the lncRNA NORAD (non-coding RNA activated by DNA damage) which, due to its high abundance and multitude of PUMILIO binding sites, is able to sequester a significant fraction of PUM1 and PUM2 in the cytoplasm (PubMed:26724866). May regulate DCUN1D3 mRNA levels (PubMed:25349211). May support proliferation and self-renewal of stem cells. Binds specifically to miRNA MIR199A precursor, with PUM1, regulates miRNA MIR199A expression at a postranscriptional level (PubMed:28431233)

The "PUM2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PUM2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets